Exley MA - Search Results

1

Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.

Wolf BJ, Choi JE, Exley MA. Wolf BJ, et al. Among authors: exley ma. Front Immunol. 2018 Mar 2;9:384. doi: 10.3389/fimmu.2018.00384. eCollection 2018. Front Immunol. 2018. PMID: 29559971 Free PMC article. Review.

2

Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.

Stolk D, van der Vliet HJ, de Gruijl TD, van Kooyk Y, Exley MA. Stolk D, et al. Among authors: exley ma. Front Immunol. 2018 Sep 21;9:1990. doi: 10.3389/fimmu.2018.01990. eCollection 2018. Front Immunol. 2018. PMID: 30298063 Free PMC article. Review.

3

A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model.

Wen X, Kim S, Xiong R, Li M, Lawrenczyk A, Huang X, Chen SY, Rao P, Besra GS, Dellabona P, Casorati G, Porcelli SA, Akbari O, Exley MA, Yuan W. Wen X, et al. Among authors: exley ma. J Immunol. 2015 Aug 15;195(4):1459-69. doi: 10.4049/jimmunol.1500574. Epub 2015 Jul 8. J Immunol. 2015. PMID: 26157173 Free PMC article.

4

Exploiting CD1-restricted T cells for clinical benefit.

Exley MA, Dellabona P, Casorati G. Exley MA, et al. Mol Immunol. 2021 Apr;132:126-131. doi: 10.1016/j.molimm.2020.12.015. Epub 2021 Feb 12. Mol Immunol. 2021. PMID: 33582549 Review.

5

Isolation and Functional Use of Human NKT Cells.

Exley MA, Wilson SB, Balk SP. Exley MA, et al. Curr Protoc Immunol. 2017 Nov 1;119:14.11.1-14.11.20. doi: 10.1002/cpim.33. Curr Protoc Immunol. 2017. PMID: 29091262

6

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Exley MA, Friedlander P, Alatrakchi N, Vriend L, Yue S, Sasada T, Zeng W, Mizukami Y, Clark J, Nemer D, LeClair K, Canning C, Daley H, Dranoff G, Giobbie-Hurder A, Hodi FS, Ritz J, Balk SP. Exley MA, et al. Clin Cancer Res. 2017 Jul 15;23(14):3510-3519. doi: 10.1158/1078-0432.CCR-16-0600. Epub 2017 Feb 13. Clin Cancer Res. 2017. PMID: 28193627 Free PMC article. Clinical Trial.

7

Invariant Natural Killer T Cells are Reduced in Hereditary Hemochromatosis Patients.

Maia ML, Pereira CS, Melo G, Pinheiro I, Exley MA, Porto G, Macedo MF. Maia ML, et al. Among authors: exley ma. J Clin Immunol. 2015 Jan;35(1):68-74. doi: 10.1007/s10875-014-0118-0. Epub 2014 Dec 6. J Clin Immunol. 2015. PMID: 25479931

8

Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells.

van der Vliet HJ, Wang R, Yue SC, Koon HB, Balk SP, Exley MA. van der Vliet HJ, et al. Among authors: exley ma. J Immunol. 2008 Jun 1;180(11):7287-93. doi: 10.4049/jimmunol.180.11.7287. J Immunol. 2008. PMID: 18490728 Free PMC article.

9

Characterization of the phenotype and function of CD8(+), alpha / beta(+) NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets.

Stremmel C, Exley M, Balk S, Hohenberger W, Kuchroo VK. Stremmel C, et al. Eur J Immunol. 2001 Sep;31(9):2818-28. doi: 10.1002/1521-4141(200109)31:9<2818::aid-immu2818>3.0.co;2-1. Eur J Immunol. 2001. PMID: 11536181 Free article.

10

iNKT cells and hematopoietic stem cell transplantation: Two-phase activation of iNKT cells may improve outcome.

Fereidouni M, Derakhshani A, Exley MA. Fereidouni M, et al. Among authors: exley ma. Clin Immunol. 2019 Oct;207:43-48. doi: 10.1016/j.clim.2019.05.011. Epub 2019 May 23. Clin Immunol. 2019. PMID: 31128279 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page